Now I have a thorough understanding of the paper and the calibration context. Let me write the consolidated review.

---

## Summary

This paper develops a method for constructing lower prediction bounds (LPBs) for counterfactual survival times under general right-censoring, combining censored quantile regression with weighted conformal prediction. The core insight — recasting the coverage problem as a covariate shift from the treated-uncensored population to the target population — is theoretically sound and extends previous PAC-type guarantees to an exact marginal coverage guarantee. The paper provides a doubly robust theoretical result and validates the method on synthetic and real-world clinical data.

## Strengths

1. **First exact marginal coverage guarantee for counterfactual survival LPBs under general right-censoring.** Theorem 4.1 provides a distribution-free bound on the coverage gap due to density-ratio estimation error, going beyond the PAC-type guarantees of prior work (Gui et al. 2024, Davidov et al. 2025). The theoretical framing connecting the counterfactual coverage problem to weighted conformal prediction is the paper's central contribution.

2. **Doubly robust guarantee (Theorem 4.2).** The procedure maintains valid coverage asymptotically if either the censoring-propensity model or the quantile regression model is consistently estimated. This is a meaningful theoretical addition not established in prior conformal survival counterfactual methods.

3. **Empirical support on synthetic data.** Figures 1 and 3 show the method consistently attains the target 90% coverage across six settings and under outlier contamination, while producing more informative LPBs than PAC-type baselines. The robustness to outliers (Figure 3) is a clear empirical advantage.

4. **Clinically meaningful real-data patterns.** On the lung cancer dataset, the LPB values align with known clinical knowledge (VMAT优于IMRT, induction/concurrent chemotherapy improves survival, lower LPB for advanced stages), demonstrating practical utility for personalized treatment comparison.

## Weaknesses

### Major

1. **The per-test-point τ optimization is not covered by the stated theoretical guarantee.** Theorem 4.1 establishes an exact coverage guarantee for a **fixed** τ. The procedure in Section 4.1 then optimizes τ per test point (τ*(x) = argmax_τ q̃_τ^{(w)}(x) − c^{(w)}_{1−α}(τ)) to maximize informativeness. Because the optimized LPB is pointwise larger than any fixed-τ LPB, the event {T(w) ≥ optimized LPB} is stricter than the fixed-τ events, so the guarantee of Theorem 4.1 does **not** automatically transfer. The paper offers no alternative justification (e.g., selection on a separate validation set, a union bound over a finite grid, or an explicit statement that the optimization is heuristic). Table 1 and Figure 11 report results using τ* without clarifying whether (or under what conditions) the guarantee holds. This severs the link between the theory and the practical algorithm as presented.

2. **The real-data coverage evaluation is insufficiently specified.** Figure 4 (top row) reports "Coverage Rate" on the lung cancer dataset, and the text claims the method "maintains the desired coverage rate" on real data. However, the paper never explains how coverage is evaluated on censored test patients, for whom the true survival time T(w) is unobserved. It does not state whether evaluation is restricted to uncensored patients (which would introduce selection bias), whether an imputation procedure is used, or whether some other protocol applies. Without this information, the real-data coverage claim is unverifiable. The main empirical support for coverage validity comes from the synthetic experiments, so this issue does not invalidate the paper's core claims, but the real-data section needs a transparent statement of its limitations.

### Minor

3. **Setting 6 coverage behavior warrants more explanation.** The proposed method's coverage dips slightly below the nominal 90% in Setting 6 (Figure 1), and its relative LPB is notably lower. The paper mentions this briefly but does not analyze why (e.g., whether weight estimation degrades under the specific censoring structure of that setting). A brief discussion would help the reader assess the method's limitations in high-censoring regimes.

4. **The description of the weight function estimation in the main text is sparse.** The estimation of γ(x) (via Random Forest) is central to the method's practical validity, yet the main text gives only one sentence on it. While more details may appear in the appendix, the main paper would benefit from a brief discussion of how the weight estimation accuracy affects coverage, especially given Theorem 4.1's dependence on the L1 error of ω̃.

### Trivial

None.

## Nice-to-Haves

- The τ optimization could be placed on a firmer footing by selecting τ on a separate validation set (preserving exchangeability) rather than per test point, or by explicitly stating it as a heuristic and evaluating its empirical cost.
- A more detailed analysis of Setting 6 would strengthen the empirical section.
- The real-data analysis would be more impactful if it included a discussion of how censored patients are handled when interpreting coverage.

## Removed Points

- *Criticism that the real-data coverage claim is "unverifiable" (Harsh Critic framing as "fatal"):* Removed from fatal tier because the paper's main empirical coverage validation comes from synthetic data where T(w) is known. The real-data coverage is a supplementary claim that needs clarification but does not undermine the paper's core evidence. Kept as Major weakness #2 (insufficiently specified).
- *Criticism about missing appendix content, proofs, or references:* Removed per rules — the parser strips these sections from all papers.
- *Generic formatting/style nitpicks:* Removed.
- *Strength Finder's generic strengths (e.g., "this paper addresses an important problem"):* Removed as lacking concrete specificity.
- *Criticism that weight training details are "relegated to the appendix":* Not a substantive weakness; the main text provides the essential algorithmic description.

## Novel Insights

The most interesting observation emerging from the reviews is the tension between the exactness emphasis of the paper's narrative and the heuristic nature of the τ-optimization step. This is a recurring pattern in conformal prediction papers: an exact theoretical guarantee is derived under a fixed tuning parameter, then a data-dependent selection is introduced for practical performance without re-proving the guarantee. The paper would be stronger if it either (a) aligned the algorithm with the theory by selecting τ on a separate validation split, or (b) provided explicit empirical evidence that the optimization does not materially degrade coverage (beyond Table 1's single-setting results). Additionally, the doubly robust theorem (Theorem 4.2) is a genuine theoretical contribution that is somewhat underexploited in the experiments — a synthetic experiment where one model is misspecified would directly demonstrate its value.

## Suggestions

1. **Clarify the τ optimization status.** Either prove the guarantee for the optimized procedure (e.g., via union bound over a discrete grid), select τ on a hold-out validation set, or explicitly state that the optimization is a heuristic and report empirical verification separately from the theorem.
2. **Explain the real-data coverage computation.** State precisely how coverage is calculated on the lung cancer dataset: which patients are included (observed events only? all patients?), and what assumptions are needed for this calculation to be valid. If coverage cannot be reliably estimated due to censoring, acknowledge this limitation.
3. **Move the τ optimization justification earlier in the paper.** A reader encounters the optimization (Section 4.1) before the theorem (Section 4.2) and may assume the guarantee applies to the optimized output. A remark such as "the following guarantee holds for any fixed τ; the per-point optimization described above is a heuristic for improving informativeness" would prevent confusion.
4. **Analyze Setting 6.** Add a brief discussion of why coverage is slightly below nominal in Setting 6 (e.g., high censoring rate, poor weight estimation) to help readers understand the method's failure modes.

## Score and Decision

**Bracket determination (Round 1):** The closest topical anchor is "Conformalized Survival Analysis for General Right-Censored Data" (avg 5.50, Accept), which solves a related but narrower problem (survival LPBs without counterfactuals). Middle-band anchors (AKAz88zYLB avg 5.80, pVL4bYKOGM avg 5.50) show that conformal-prediction-for-causal-effects papers on similar methodology tend to score in the 5.5–6.0 range but are often rejected for insufficient novelty or validation gaps. Initial bracket: 4.5–6.5.

**Narrowing (Round 2):** Closer comparison against the 5.50 anchor (JQtuCumAFD) and 6.00 anchors (j511LaqEeP, Nfd7z9d6Bb) shows this paper has a stronger contribution than the 5.50 anchor (it adds counterfactual prediction and exact coverage) but weaker execution due to the τ-optimization disconnect and the unspecified real-data coverage protocol. Equalizing these factors places the paper slightly below the 5.50 anchor.

**Final score:** 5.0

**Decision:** Reject

This is a borderline paper with a genuine theoretical contribution and promising empirical direction. The core idea — transforming counterfactual survival LPB into a weighted conformal problem — is valuable and well-motivated. However, the disconnect between the theoretical guarantee (fixed τ) and the practical algorithm (optimized τ) creates a coherence problem that the paper must resolve. The real-data coverage evaluation also requires clarification. With these issues addressed, the paper could be suitable for acceptance at a future venue.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>